Fate Therapeutics Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Fate Therapeutics, Inc. (NASDAQ: FATE) has announced its participation in three upcoming investor conferences. The events include the Stifel Healthcare Virtual Conference on November 17, 2020, Jefferies Global Healthcare Virtual Conference on November 19, 2020, and Evercore ISI HealthCONx Virtual Conference on December 1, 2020. Each event will feature a live webcast available on the company's investor relations section. Fate Therapeutics focuses on developing cellular immunotherapies for cancer and immune disorders, utilizing its proprietary iPSC platform.

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:

• Stifel Healthcare Virtual Conference on Tuesday, November 17, 2020 from 4:00-4:30PM ET
• Jefferies Global Healthcare Virtual Conference on Thursday, November 19, 2020 from 9:05-9:35AM ET
• Evercore ISI HealthCONx Virtual Conference on Tuesday, December 1, 2020 from 3:30-3:50PM ET
  

A live webcast, if recorded, of each presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following each live webcast, an archived replay will be available on the Company's website for 30 days.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com 

 

FAQ

When is the Fate Therapeutics presentation at the Stifel Healthcare Virtual Conference?

Fate Therapeutics will present at the Stifel Healthcare Virtual Conference on November 17, 2020, from 4:00-4:30 PM ET.

What is the schedule for Fate Therapeutics at upcoming investor conferences?

Fate Therapeutics will participate in the following conferences: Stifel Healthcare on November 17, Jefferies Global Healthcare on November 19, and Evercore ISI HealthCONx on December 1, 2020.

Where can I watch the Fate Therapeutics conference presentations?

The presentations will be available via live webcast on the investor relations section of Fate Therapeutics' website.

What type of therapies does Fate Therapeutics develop?

Fate Therapeutics develops cellular immunotherapies for cancer and immune disorders, focusing on off-the-shelf cell products and immuno-oncology candidates.

What is the significance of Fate Therapeutics' iPSC product platform?

Fate Therapeutics' iPSC product platform allows for the development of universal, off-the-shelf cell products for cancer treatments, enhancing efficacy when paired with existing therapies.